Carmell Therapeutics gets IND clearance for CT-101 bone healing accelerant
Carmell Therapeutics has secured clearance from the US Food and Drug Administration (FDA) for its investigational new drug application (IND) for CT-101, its first product, which is a bone healing accelerant (BHA). The Pennsylvania biotech company is engaged in the development and commercialization of plasma-based bioactive materials (PBMs) to speed up bone and soft tissue […]